摘要
卵巢癌是女性生殖系统常见的恶性肿瘤之一。卵巢癌由于早期症状不明显,导致多数患者发现时已届晚期,而肿瘤的高侵袭性与耐药性是造成晚期卵巢癌患者预后不良的主要原因。因此,寻找与卵巢癌侵袭性和耐药性相关的活性物质及早期生物标志物是目前卵巢肿瘤研究的主要方向。激肽释放酶相关肽酶(kallikrein-related peptidases,KLKs),即组织激肽释放酶,是一组由15个家族成员组成的分泌型丝氨酸蛋白酶,具有多种组织特异性表达谱,能够通过调节细胞因子与蛋白酶的活性,激活细胞膜受体以及水解细胞外基质等发挥其病理和生理作用。目前已有研究表明,KLKs在卵巢癌中呈现特征性表达,并且与卵巢癌细胞的侵袭及耐药性具有密切的联系。本文将对KLK家族与卵巢癌发生、发展、转移、侵袭及耐药性的关系进行综述。
Ovarian cancer is one of the most common gynecological malignancies. Most patients were diagnosed of ovarian cancer at advanced stages due to non-obviousness of early symptoms. Both of metastasis and drug resistance are the main causes for poor prognosis of patients with ovarian cancer. Therefore, the current hotspots for ovarian cancer research focus on identification of early biomarkers related to metastasis and drug resistance. Kallikrein- related peptidases （KLKs）, also known as tissue kallikreins--a group of secreted serine proteases including fifteen members, have diverse tissue-specific expression profiles and mediate a range of pathological and physiological processes mainly through regulating the bioactivity of certain cytokines and proteases, activating cell membrane receptors or hydrolyzing extracellular matrix. Many studies have showed that KLKs are aberrantly expressed in ovarian cancer and involved in cancer development, metastasis and drug resistance. This review highlights the advances in relationship ofKLKs family with occurrence, development, metastasis, invasion and drug resistance of ovarian cancer.
出处
《肿瘤》
CAS
CSCD
北大核心
2015年第12期1387-1395,共9页
Tumor
关键词
卵巢肿瘤
组织激肽释放酶类
基因表达
肿瘤转移
抗药性
肿瘤
Ovarian neoplasms
Tissue kallikreins
Gene expression Neoplasmmetastasis
Drug resistance, neoplasm
